Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus X TROZINE L A.
CYPROHEPTADINE HYDROCHLORIDE vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine
Antihistamine